Five things for pharma marketers to know: Thursday, April 19, 2018
There's a bidding war for Shire. Allergan is reportedly in talks to acquire the drugmaker, putting it in competition with Takeda Pharmaceutical to buy the $50 billion company. (Reuters) Shire rejected Takeda's $60 billion takeover bid on Thursday. (Business Insider).
The number of opioid prescriptions dropped significantly in 2017. Opioid prescriptions dropped by 9% last year across the country and by more than 5% in all 50 states and the District of Columbia, according to data from IQVIA. (Associated Press)
Shares of Eli Lilly were down this morning after the FDA raised concerns about its rheumatoid arthritis drug baricitinib. The drug is set to go before the FDA's RA advisory committee on Monday. (MarketWatch)
Novartis issued disappointing first-quarter results, its first under CEO Vas Narasimhan. A sales slump by its American generics unit and its psoriasis drug missing expectations in the period. (Reuters)
Segway inventor Dean Kamen's next goal is reinventing healthcare. His new company, ARMI, wants to kickstart an industry that can produce human organs and tissue from recipients' own cells. Kamen is backed by several government agencies. (CNBC)